All News

FDA authorized Aletta, a robotic venous blood collection device for supervised outpatient use, through the De Novo pathway.

Josef Coresh, MD, discusses biomarkers, hearing correction, and integrated vascular care as emerging dementia prevention strategies.

FDA approved garetosmab for adults with FOP after phase 3 data showed fewer new HO lesions and clinician-assessed flare-ups vs placebo.

If approved, ecopipam would be the first new therapy indicated for pediatric patients with Tourette syndrome in more than 10 years.

A nurse practitioner discusses why once-weekly basal insulin matters, who benefits most, and how its starting doses differ from daily insulin.

Phase 3 LUCIDITY results showed avexitide reduced Level 2 and Level 3 hypoglycemic events by 55% vs placebo in post-bariatric hypoglycemia.

The FDA approved an autoinjector device for lerodalcibep-liga and an updated indication reflecting cardiovascular risk reduction.

Stepped reminders to PCPs and patients increased annual lung cancer screening adherence by 27.7 percentage points, according to new research.

A Swedish observational study linked NOAC use to slower cognitive decline in individuals with atrial fibrillation and Alzheimer disease.

The US FDA granted breakthrough device status to Freenome’s investigational blood test designed to triage high-risk adults for lung cancer screening.

Josef Coresh, MD, PhD, discusses how primary care clinicians can address hypertension, diabetes, and smoking to support long-term cognitive health.

The organizations challenge a presidential executive order narrowing routine childhood vaccine recommendations and urging vaccines to be given separately.

Insulin icodec is now available in the US after FDA approval, offering adults with type 2 diabetes a once-weekly basal insulin option.

Corresponding author Josef Coresh, MD, PhD, explains how hypertension, diabetes, and smoking in midlife were linked to fewer dementia-free survival years.

Topline phase 2 data showed single-dose ABCL635 reduced moderate-to-severe vasomotor symptom frequency by 83% at week 4.

FDA acceptance starts review of clesrovimab for second-season RSV prevention in high-risk children younger than 2 years.

Fendrick considers the current state of colorectal cancer screening in the US, emphasizing limited colonoscopy capacity and patient preferences for at-home tests.

The FDA approved oveporexton for narcolepsy type 1 in adults, marking the first orexin receptor agonist targeting the underlying biological cause of narcolepsy.